Treatments are gentle and well-tolerated
Qian, E., Poojar, P., Vaughan, J
Choosing between IV and oral glutathione requires weighing bioavailability against safety, cost, and convenience factors
Phase Weeks 1-2 Draw volume 7.5 units (0.075 mL) Total blend delivered ~2.0 mg total blend GHK-Cu ~1.25 mg KPV ~250 mcg BPC-157 ~250 mcg TB-500 ~250 mcg Phase Weeks 3-4 Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Phase Weeks 5-8 Draw volume 22.5 units (0.225 mL) Total blend delivered ~6.0 mg total blend GHK-Cu ~3.75 mg KPV ~750 mcg BPC-157 ~750 mcg TB-500 ~750 mcg Phase Weeks 9-12 (taper) Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Blend ratio 50 / 10 / 10 / 10 mg GHK-Cu dominant Select a draw volume from the titration table above to see the approximate amount of each peptide delivered
Cycle Guidelines Approach Standard Duration 4-6 weeks Review point Week 4 Best for General research planning Approach Extended Duration 6-8 weeks Review point Week 6 Best for Stubborn-injury research models Approach Long Duration 8-12 weeks Review point Week 8 Best for Slow-remodeling tissue research planning Off periods of 2-4 weeks between cycles are common in research planning
There is no significant downtime, and clients can return to daily activities right after the procedure
